Behavioural Pharmacology · 2006 · 51 citations · 38 references
MedicineNeurosciencePharmacologyBehavioral NeuroscienceBehavioral PharmacologyNeuropharmacologyDopaminergic PharmacologyMonoamine NeurochemistryNeurochemical PharmacologyNeuroprotectionNeuroprotective PharmacologyParkinson DiseaseModafinil PharmacologyModafinil TherapyNeurobehavioral Effects Of IntoxicationNeuroprotective AgentsNeuroprotective MechanismsNeuroprotective PharmacotherapyNigrostriatal Dopamine PathwayParkinsonian Neuroprotection
The vigilance-enhancing agent modafinil has neuroprotective properties: it prevents striatal ischemic injury, nigrostriatal pathway deterioration after partial transsection and intoxication with 1-methyl-1,2,3,6-tetrahydropyridine. The present study determines the protective effects of modafinil in the marmoset 1-methyl-1,2,3,6-tetrahydropyridine Parkinson model on behavior and on monoamine levels. Twelve marmoset monkeys were treated with a total dose of 6 mg/kg 1-methyl-1,2,3,6-tetrahydropyridine. Simultaneously, six animals received a daily oral dose of modafinil (100 mg/kg) and six animals received vehicle for 27 days. Behavior was observed daily and the locomotor activity, hand-eye coordination, small fast movements, anxiety-related behavior and startle response of the animals were tested twice a week for 3 weeks. Modafinil largely prevented the 1-methyl-1,2,3,6-tetrahydropyridine-induced change in observed behavior, locomotor activity, hand-eye coordination and small fast movements, whereas the vehicle could not prevent the devastating effects of 1-methyl-1,2,3,6-tetrahydropyridine. Dopamine levels in the striatum of the vehicle+1-methyl-1,2,3,6-tetrahydropyridine-treated animals were reduced to 5% of control levels, whereas the dopamine levels of the modafinil+1-methyl-1,2,3,6-tetrahydropyridine-treated animals were reduced to 41% of control levels. The present data suggest that modafinil prevents decrease of movement-related behavior and dopamine levels after 1-methyl-1,2,3,6-tetrahydropyridine intoxication and can be an efficaceous pharmacological intervention in the treatment of Parkinson's disease.
38
Staging of brain pathology related to sporadic Parkinson’s disease
Heiko Braak, Kelly Del Tredici, Udo Rüb et al. · Neurobiology of Aging · 2002 · 10.8K citations
Medicine, Neurology, Neuroscience +13
Dopaminergic Role in Stimulant-Induced Wakefulness
Jonathan P. Wisor, Seiji Nishino, Ichiro Sora et al. · Journal of Neuroscience · 2001 · 762 citations · Full text